Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
— Third Consecutive Year of Phexxi Net Sales Growth —
— Total Operating Expense Reduced 64% from 2022 Levels —
— Sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the Phexxi launch —
Related news for (EVFM)
- FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences’ “One and Done” Oral Treatment for Bacterial Vaginosis and Trichomoniasis
- Evofem Biosciences to Present at Emerging Growth Conference
- Windtree Therapeutics Strikes Deal to Source PHEXXI, Signaling Revenue-Driven Pivot
- Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
- Evofem Biosciences Announces Financial Results for the Second Quarter of 2024